We therefore determined whether agonist anti-CD40 mAb (FGK45.5 or FGK) in combination with PPARγ (T0070907 or T007) or PPARδ (GSK3787 or GSK) inhibitor may achieve efficient antitumor responses in mice with established B16 melanoma (Fig. 1a, left). This evidence concerns the gene CD40 and melanoma.